What Researchers Did
Researchers conducted a multicenter, prospective, observational study in Japan to clarify acute carbon monoxide (CO) poisoning treatment and investigate hyperbaric oxygen (HBO2) therapy's efficacy in preventing delayed neurological sequelae (DNS).
What They Found
Out of 255 analyzed patients with acute CO poisoning, 171 received hyperbaric oxygen (HBO2) therapy and 84 received normobaric oxygen (NBO2). The incidence of delayed neurological sequelae (DNS) was 7.6% (13/171) in the HBO2 group and 3.6% (3/84) in the NBO2 group (P = 0.212). The number of HBO2 sessions within the first 24 hours was associated with DNS incidence (odds ratio, 2.082; P = 0.024).
What This Means for Canadian Patients
This study suggests that hyperbaric oxygen therapy for carbon monoxide poisoning might not significantly reduce delayed neurological sequelae, although the number of sessions could be a factor. Canadian patients should discuss treatment options for carbon monoxide poisoning with their healthcare providers, considering current guidelines and individual circumstances.
Canadian Relevance
This study was conducted in Japan and has no direct Canadian connection.
Study Limitations
A key limitation is the observed variability in practical clinical treatment, including hyperbaric oxygen therapy protocols, across participating institutions in Japan.